Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.

  • Pisoni R
  • Acelajado M
  • Cartmill F
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Hypertension is a major risk factor for the development and progression of chronic kidney disease (CKD). Mineralocorticoid receptor antagonists (MRAs) are effective in the management of resistant hypertension but are not widely used in CKD because of the risk of hyperkalemia. We retrospectively evaluated the long-term effects and safety of MRAs added to a pre-existing antihypertensive regimen in subjects with resistant hypertension associated with stage 3 CKD. In all, 32 patients were treated with spironolactone and 4 with eplerenone for a median follow-up of 312 days. MRAs induced a significant decrease in systolic blood pressure from 162±22 to 138±14 mm Hg (P

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • R Pisoni

  • M C Acelajado

  • F R Cartmill

  • T Dudenbostel

  • L J Dell'italia

  • S S Cofield

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free